Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Tanja Dolinšek) .

1 - 10 / 23
First pagePrevious page123Next pageLast page
1.
Effects of electrochemotherapy on immunologically important modifications in tumor cells
Urša Kešar, Boštjan Markelc, Tanja Jesenko, Katja Uršič Valentinuzzi, Maja Čemažar, Primož Strojan, Gregor Serša, 2023, original scientific article

Abstract: Electrochemotherapy (ECT) is a clinically acknowledged method that combines the use of anticancer drugs and electrical pulses. Electrochemotherapy with bleomycin (BLM) can induce immunogenic cell death (ICD) in certain settings. However, whether this is ubiquitous over different cancer types and for other clinically relevant chemotherapeutics used with electrochemotherapy is unknown. Here, we evaluated in vitro in the B16-F10, 4T1 and CT26 murine tumor cell lines, the electrochemotherapy triggered changes in the ICD-associated damage-associated molecular patterns (DAMPs): Calreticulin (CRT), ATP, High Mobility Group Box 1 (HMGB1), and four immunologically important cellular markers: MHCI, MHC II, PD-L1 and CD40. The changes in these markers were investigated in time up to 48 h after ECT. We showed that electrochemotherapy with all three tested chemotherapeutics induced ICD-associated DAMPs, but the induced DAMP signature was cell line and chemotherapeutic concentration specific. Similarly, electrochemotherapy with CDDP, OXA or BLM modified the expression of MHC I, MHC II, PD-L1 and CD40. The potential of electrochemotherapy to change their expression was also cell line and chemotherapeutic concentration specific. Our results thus put the electrochemotherapy with clinically relevant chemotherapeutics CDDP, OXA and BLM on the map of ICD inducing therapies.
Keywords: electrochemotherapy, cisplatin, immune response
Published in DiRROS: 21.03.2024; Views: 50; Downloads: 28
.pdf Full text (7,17 MB)
This document has many files! More...

2.
3.
Razvoj in karakterizacija mišjega modela za študije HPV-pozitivnega raka glave in vratu
Živa Modic, Maja Čemažar, Boštjan Markelc, Andrej Cör, Gregor Serša, Simona Kranjc Brezar, Tanja Jesenko, 2023, published scientific conference contribution abstract

Keywords: miši, rak glave in vratu, gensko zdravljenje
Published in DiRROS: 19.06.2023; Views: 338; Downloads: 146
.pdf Full text (361,47 KB)
This document has many files! More...

4.
Aktivacija vzorčno prepoznavnih senzorjev po genskem elektroprenosu plazmida z zapisom za interlevkin-12
Ajda Medved, Tanja Jesenko, Gregor Serša, Maša Omerzel, Maja Čemažar, 2023, published scientific conference contribution abstract

Keywords: miši, obsevanje, gensko zdravljenje
Published in DiRROS: 19.06.2023; Views: 301; Downloads: 139
.pdf Full text (457,33 KB)
This document has many files! More...

5.
6.
Sproščanje dejavnikov imunogene celične smrti HMGB1 in ATP iz celičnih linij se povečuje s časom po obsevanju
Urša Kešar, Tanja Jesenko, Boštjan Markelc, Katja Uršič Valentinuzzi, Maja Čemažar, Primož Strojan, Gregor Serša, 2023, published scientific conference contribution abstract

Keywords: miši, obsevanje, radioterapija
Published in DiRROS: 19.06.2023; Views: 296; Downloads: 138
.pdf Full text (432,50 KB)
This document has many files! More...

7.
8.
9.
10.
Maintenance and gene electrotransfer efficiency of antibiotic resistance gene-free plasmids encoding mouse, canine and human interleukin-12 orthologues
Urška Kamenšek, Andrej Renčelj, Tanja Jesenko, Tinkara Remic, Gregor Serša, Maja Čemažar, 2022, original scientific article

Abstract: Interleukin 12 (IL-12) is a cytokine used as a therapeutic molecule in cancer immunotherapy. Gene electrotransfer mediated delivery of IL-12 gene has reached clinical evaluation in the USA using a plasmid that in addition to IL- 12 gene also carry an antibiotic resistance gene needed for its production in bacteria. In Europe however, Eu- ropean Medicines Agency recommends against the use of antibiotics during the production of clinical grade plasmids. We have prepared several antibiotic resistance gene-free plasmids using an antibiotic-free selection strategy called operator-repressor titration, including plasmids encoding mouse, canine and human IL-12 orthologues. The aim of this study was to evaluate the maintenance of these plasmids in bacterial culture and test their transfection efficiency using gene electrotransfer. Plasmid maintenance was evaluated by determining plasmid yields and topologies after subculturing transformed bacteria. Transfection efficiency was evaluated by determining the plasmid copy number, expression and cytotoxicity after gene electrotransfer to mouse, canine and human melanoma cells. The results demonstrated that our IL-12 plasmids without an antibiotic resistance gene are stably maintained in bacteria and provide sufficient IL-12 expression after in vitro gene electrotransfer; therefore, they have the potential to proceed to further in vivo evaluation studies.
Keywords: electrotransfer, interleukin-12, immunotherapy, mammals
Published in DiRROS: 23.09.2022; Views: 532; Downloads: 246
.pdf Full text (2,13 MB)
This document has many files! More...

Search done in 0.33 sec.
Back to top